Literature DB >> 17553935

Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein E knockout mice.

Tomoya Yamashita1, Seinosuke Kawashima, Tetsuaki Hirase, Masakazu Shinohara, Tomofumi Takaya, Naoto Sasaki, Masafumi Takeda, Hideto Tawa, Nobutaka Inoue, Ken-Ichi Hirata, Mitsuhiro Yokoyama.   

Abstract

Atherosclerosis is a complex chronic inflammatory disease in which macrophages play a critical role, and the intervention of the inflammatory process in atherogenesis could be a therapeutic strategy. In this study, we investigated the efficacy of xenogenic macrophage immunization on the atherosclerotic lesion formation in a model of murine atherosclerosis. Apolipoprotein E knockout (apoE-KO) mice were repeatedly immunized with formaldehyde-fixed cultured human macrophages (phorbol ester-stimulated THP-1 cells), using human serum albumin as a control protein or HepG2 cells as human control cells, once a week for four consecutive weeks. The vehicle phosphate-buffered saline was injected in the nonimmunized controls. THP-1 immunization induced antibodies that are immunoreactive with mouse macrophages. Although the plasma lipid levels were unchanged by the immunization, the atherosclerotic lesion area in the aortic root was significantly reduced by >50% in 16-wk-old THP-1-immunized apoE-KO mice compared with that in control mice. THP-1 immunization reduced in vivo macrophage infiltration, reduced in vitro macrophage adhesion, and changed cytokine production by macrophages to the antiatherogenic phenotype. Xenogenic macrophage immunization protects against the development of atherosclerosis in apoE-KO mice by modulating macrophage function in which antibodies induced by the immunization are likely to be involved. This method is a novel and potentially useful cell-mediated immune therapeutic technique against atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17553935     DOI: 10.1152/ajpcell.00117.2007

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  2 in total

1.  Boosted rat natural xenoantibodies cross-react with Enterococcus faecalis by targeting melibiose and L-rhamnose.

Authors:  Magdiel Perez-Cruz; Cristina Costa; Rafael Mañez
Journal:  J Innate Immun       Date:  2013-11-15       Impact factor: 7.349

2.  CD3 antibody and IL-2 complex combination therapy inhibits atherosclerosis by augmenting a regulatory immune response.

Authors:  Kazuyuki Kasahara; Naoto Sasaki; Tomoya Yamashita; Tomoyuki Kita; Keiko Yodoi; Yoshihiro Sasaki; Masafumi Takeda; Ken-Ichi Hirata
Journal:  J Am Heart Assoc       Date:  2014-04-22       Impact factor: 5.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.